What the FDA labels say about taking them together
Amphetamine and dextroamphetamine
Dextroamphetamine's FDA label of November 26, 2025 names amphetamine in its contraindications section; amphetamine's label does not name dextroamphetamine itself but warns about its class (Stimulants). The dextroamphetamine label: “DRUG INTERACTIONS Acidifying and Alkalinizing Agents: Agents that alter GI and urinary pH can alter blood levels of amphetamine.”
Check it at the source: the amphetamine FDA label on DailyMed (effective August 20, 2026, Aurolife Pharma, LLC); the dextroamphetamine FDA label on DailyMed (effective November 26, 2025, Azurity Pharmaceuticals, Inc.).
What does the amphetamine label say about dextroamphetamine?
Amphetamine's label does not name dextroamphetamine itself; it warns about its class (Stimulants):
Amphetamine label, boxed warningMISUSE AND ABUSE OF CNS STIMULANTS, INCLUDING AMPHETAMINE SULFATE, CAN RESULT IN OVERDOSE AND DEATH (SEE OVERDOSAGE)], AND THIS RISK IS INCREASED WITH HIGHER DOSES OR UNAPPROVED METHODS OF ADMINISTRATION, SUCH AS SNORTING OR INJECTION.
Amphetamine label, warningsIf concomitant use of Amphetamine Sulfate Tablets with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate Amphetamine Sulfate Tablets with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome. …
Source: FDA drug label (Amphetamine Sulfate), Aurolife Pharma, LLC, effective August 20, 2026 (SPL set 20735c2e-6304-425f-a4e4-584f6f90d6a0), via openFDA; the full label on DailyMed
What does the dextroamphetamine label say about amphetamine?
Dextroamphetamine label, contraindicationsCONTRAINDICATIONS Known hypersensitivity to amphetamine products.
Dextroamphetamine label, drug interactionsUrinary acidifying agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.
Dextroamphetamine label, warningsAmphetamine sulfate can be diverted for non-medical use into illicit channels or distribution (see DRUG ABUSE and DEPENDENCE ).
Xelstrym label (Noven Therapeutics, LLC, December 23, 2025), contraindicationsCONTRAINDICATIONS XELSTRYM is contraindicated in patients: with known hypersensitivity to amphetamine products or other components of XELSTRYM.
Xelstrym label (Noven Therapeutics, LLC, December 23, 2025), drug interactionsDRUG INTERACTIONS Acidifying and Alkalinizing Agents: Agents that alter GI and urinary pH can alter blood levels of amphetamine.
Xelstrym label (Noven Therapeutics, LLC, December 23, 2025), warnings and precautionsPatients who develop contact sensitization to XELSTRYM and require oral treatment with amphetamine should be initiated on oral medication under close medical supervision.
Source: FDA drug label (Xelstrym, NDA215401), Noven Therapeutics, LLC, effective December 23, 2025 (SPL set 0862f02a-72a8-41cc-8845-57cf4974bb6f), via openFDA
Source: FDA drug label (Zenzedi), Azurity Pharmaceuticals, Inc., effective November 26, 2025 (SPL set d6394df5-f2c9-47eb-b57e-f3e9cfd94f84), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Amphetamine | Dextroamphetamine | |
|---|---|---|
| Labeled for | ADHD | ADHD |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.449 per tablet 10 mg tablet | $0.373 per tablet 10 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once